Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer

MYC通过表观遗传抑制STING促进三阴性乳腺癌的免疫逃逸和对免疫检查点抑制剂的耐药性

阅读:4
作者:Kyung-Min Lee ,Chang-Ching Lin ,Alberto Servetto ,Joonbeom Bae ,Vishal Kandagatla ,Dan Ye ,GunMin Kim ,Dhivya R Sudhan ,Saurabh Mendiratta ,Paula I González Ericsson ,Justin M Balko ,Jeon Lee ,Spencer Barnes ,Venkat S Malladi ,Siamak Tabrizi ,Sangeetha M Reddy ,Seoyun Yum ,Ching-Wei Chang ,Katherine E Hutchinson ,Susan E Yost ,Yuan Yuan ,Zhijian J Chen ,Yang-Xin Fu ,Ariella B Hanker ,Carlos L Arteaga

Abstract

The MYC oncogene is frequently amplified in triple-negative breast cancer (TNBC). Here, we show that MYC suppression induces immune-related hallmark gene set expression and tumor-infiltrating T cells in MYC-hyperactivated TNBCs. Mechanistically, MYC repressed stimulator of interferon genes (STING) expression via direct binding to the STING1 enhancer region, resulting in downregulation of the T-cell chemokines CCL5, CXCL10, and CXCL11. In primary and metastatic TNBC cohorts, tumors with high MYC expression or activity exhibited low STING expression. Using a CRISPR-mediated enhancer perturbation approach, we demonstrated that MYC-driven immune evasion is mediated by STING repression. STING repression induced resistance to PD-L1 blockade in mouse models of TNBC. Finally, a small-molecule inhibitor of MYC combined with PD-L1 blockade elicited a durable response in immune-cold TNBC with high MYC expression, suggesting a strategy to restore PD-L1 inhibitor sensitivity in MYC-overexpressing TNBC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。